Jun 13, 2023 / 08:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Here we are. And welcome back from lunch, everybody. I hope everyone enjoyed that last panel discussion. Always informative to hear from the dark side. The opportunity now is to have the afternoon session kick off.
I'm very pleased to have Johnson & Johnson with us once again. And this is a very timely discussion, especially given all the changes that are happening with the company in terms of the rising prominence of the pharmaceutical division and we're especially pleased to have 2 of the leadership here from the oncology division, which is, I think, really the division of the business that really moves the needle here.
Biljana Naumovic who is Worldwide Vice President of Oncology, with a particular focus on commercial operations. We've had discussions with you previously, and you're probably familiar to a bunch of some of the investors as well. And then Mark Wildgust. Mark is an oncology specialist as well, medical affairs. And we're glad that you could come in here and pitch it to make sure that we
Johnson & Johnson at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers